Drug Approval | April 17, 2026
Morepen Laboratories secures fourth consecutive USFDA ‘NIL 483’ inspection
Zero-observation outcomes strengthen global credibility and accelerate CDMO ambitions
Zero-observation outcomes strengthen global credibility and accelerate CDMO ambitions
Panacea Biotec receives LoA from CMSS
This inspection is now closed
Inspection included drug device combinations covering our recent filing in nasal sprays domain
These observations are procedural in nature and the company does not anticipate any impact on supply of its commercial products
USFDA determines Sun Pharma's Baska facility inspection classification as OAI
The inspection concluded with one minor observation in Form 483
The company will respond to the US FDA within the stipulated timelines
Ipca Laboratories receives three observations from USFDA for API facility at Tarapur
The Unit is approved by major regulators like EMA, Europe; Health Canada, Anvisa, Brazil and TGA, Australia
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
